Alexandria Forbes, Ph.D. is the President and CEO of MeiraGTx (NASDAQ: MGTX). MeiraGTx is a genetic medicines company with four late stage Phase 3 and pivotal programs each using local delivery of small doses resulting in disease modifying effects in both inherited and more common diseases. MeiraGTx’s broad pipeline is supported by innovative technology in viral vector optimization leading to best in class, potent, low dose therapeutics. MeiraGTx has built the most comprehensive manufacturing capabilities in the industry with the leading manufacturing process, reducing development timelines and significantly reducing cost of goods. In addition, MeiraGTx has developed a novel technology for in vivo delivery of biologic therapeutics using oral small molecules. This drives in vivo production of native forms of short-lived peptides with physiological timing that results in transformative improvements in efficacy and tolerability in biologically responsive systems such as metabolic disease and cell therapy.

Before founding MeiraGTx, Dr. Forbes served as Senior Vice President of Commercial Operations at Kadmon Holdings, Inc., and prior to that she spent a decade as a healthcare public markets investor, initially at Galleon and then Argus/Sivik Healthcare Partners where she was responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics public equities and was portfolio manager of the Sivik Global Life Science Fund, a long-biased public markets biotechnology fund.

Before entering the hedge fund industry, Dr. Forbes was an academic scientist studying the regulation of stem cell identity and embryogenesis. She was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, a research fellow at Duke University and at the Carnegie Institute at Johns Hopkins University where her work focused on identifying the pathways of hedgehog signaling in Drosophila adult and embryo. Dr Forbes received her Ph.D. in Molecular Genetics from Oxford University, UK and attained a double first degree in Natural Sciences from Cambridge University, UK. Dr. Forbes serves on the Board of Directors of MeiraGTx, and as a Trustee and Director of the Hilary and Galen Weston Foundation and sits on the Penn Medicine Department of Medical Ethics and Health Policy External Advisory Board, and the Board of Biotech Innovation Organization (BIO).